timothy sykes logo

Stock News

iSpecimen Announces Securities Amendment Under Securities Act of 1933

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 9/14/2025, 9:18 am ET 9/14/2025, 9:18 am ET | 5 min 5 min read
iSpecimen Announces Securities Amendment Under Securities Act of 1933 Thumbnail

iSpecimen Inc.’s stocks have been trading up by 43.95 percent following significant news of key industry advancements and partnerships.

Healthcare industry expert:

Analyst sentiment – negative

iSpecimen (ISPC) finds itself in a precarious market position, as evidenced by its significantly negative profitability ratios, including an EBIT margin of -187.5% and a gross margin of merely 32.6%. The company’s income statements reveal a declining revenue trend with a five-year growth of just 2.59%, coupled with a staggering negative profit margin on total and continuing operations. The valuation ratios provide little comfort, with a high price-to-book ratio of 17.37, suggesting overvaluation amidst a backdrop of diminishing returns. A concerning quick ratio of 0.1 and a working capital deficit of -$4 million underscore financial vulnerabilities, highlighting liquidity issues that could hinder operational flexibility moving forward.

Technically, ISPC shows a volatile trading pattern, with a recent uptick from 0.74 to 1.9002 within a week. This surge formed a broad upward channel with strong bullish momentum, confirmed by rising volumes. ISPC’s price action displays potential resistance near the psychological level of 2.00, suggesting possible profit-taking scenarios. The dominant trend appears bullish, indicating a speculative buying opportunity, contingent upon breaching this resistance. Traders may consider entering long positions upon confirmation of a sustained break above this threshold, targeting 2.20, while employing tight stop-loss orders at 1.75 to manage downside risks.

Recent news indicating the intent to sell 1.56M shares signifies potential downward pressure on ISPC’s stock price due to increased supply. The Form S-1/A announcement highlights ongoing capital-raising activities, which may dilute existing shareholder value. Within the context of its sector, ISPC underperforms relative to Healthcare industry norms and particularly lags in metrics compared to the broader Healthcare Providers & Services benchmarks. While the stock has shown recent technical improvements, these news-driven events cloud the immediate outlook. ISPC faces resistance close to 2.00, with interim support levels near 1.50. Given its current trajectory and external catalysts, the sentiment remains cautious until further financial stabilization is evident.

  • iSpecimen has also filed to sell 1.56 million shares of common stock. This move is set to affect existing shareholders by potentially altering the company’s share distribution dynamics.

Candlestick Chart

Weekly Update Sep 08 – Sep 12, 2025: On Sunday, September 14, 2025 iSpecimen Inc. stock [NASDAQ: ISPC] is trending up by 43.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The recent actions by iSpecimen are indicative of a significant period of financial maneuvering. The data showcases fluctuating stock prices with iSpecimen’s shares moving between $0.74 and $1.95 over the recent days, reflecting a period of volatility. A closer look at their key financial ratios paints a vivid picture of their current challenges and aspirations.

Annual revenue stands at approximately $9.29M, yet the profit margins remain under intense pressure. The EBIT margin is deeply negative at -187.5%, and both the operating and net incomes are substantially in the red, with the latter reaching -$1,047,243 for the quarter ending June 30, 2025. Despite the alarming profitability metrics, iSpecimen retains a gross margin of 32.6%, highlighting their ability to generate revenue above direct costs. Still, the questions surrounding their long-term financial health are underscored by a total debt-to-equity ratio of 0.46 and a quick ratio of 0.1, pointing to liquidity concerns.

These strategies form part of a broader financial plan as evidenced by the securities amendment filed. As iSpecimen continues its financial recalibrations, observers will need to pay close attention to their capital management efficiencies and revenue growth techniques amid a precarious balance sheet.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”